Phenytoin-induced reduction of voriconazole serum concentration is not compensated by doubling the dosage.
J. Alffenaar,K. V. D. van der Elst,D. Uges,J. Kosterink,S. Daenen
DOI: https://doi.org/10.1111/j.1365-2125.2009.03464.x
2009-09-01
British Journal of Clinical Pharmacology
Abstract:Phenytoin is a commonly used antiepileptic agent that also has a place in the prophylaxis of seizures in patients with haematological malignancies. It is co-administered in patients receiving busulfan and in patients with meningeal involvement of haematological malignancies. As patients with these disorders encounter prolonged chemotherapy-induced neutropenia, they are at risk of bacterial and fungal infections. For the treatment of invasive pulmonary aspergillosis (IPA), one of the predominant fungal infections in these patients, voriconazole has been recommended as the first line agent [1]. However, voriconazole is extensively metabolized by CYP2C9 and CYP2C19 and, to a lesser extent, by CYP3A4 and at the same time inhibits CYP2C9 and CYP3A4. Phenytoin is widely known for inducing CYP3A4 as well as CYP2C9 and CYP2C19 activity. Besides this, it is a substrate of CYP2C9 and CYP2C19. This drug–drug interaction was recognized earlier and therefore evaluated in a prospective study in healthy volunteers [2]. This study showed that phenytoin in a dose of 300 mg once daily reduced the area under the concentration–time curve (AUC) of voriconazole given in a dose of 200 mg twice daily by 69%. From the same study it appeared that a dose increase of voriconazole to 400 mg twice daily, while receiving phenytoin 300 mg once daily, resulted in an AUC increase by 39%. The authors concluded that increasing the dose of voriconazole from 200 mg twice daily to 400 mg twice daily compensated for the effect of phenytoin on voriconazole AUC and this statement was incorporated in the product information [3].
In our institute, we monitor voriconazole serum trough concentrations regularly in patients with an invasive fungal infection. Serum samples are measured by liquid chromatography tandem mass spectrometry with a validated method of analysis. When phenytoin is co-administrated, the dosage of voriconazole is increased to 400 mg twice daily according to the manufacturer's advice. From the hospital database (2007–2009) we retrieved three Caucasian patients (49–57 years; two female, one male) with a diagnosis of malignant lymphoma who received co-medication with both agents and in whom the voriconazole and phenytoin serum concentrations were evaluated. Despite the increased dose, very low voriconazole serum concentrations (0.1–0.2 mg l−1) were observed at steady state in all three patients. The patients had received voriconazole as empiric treatment for IPA in a dose of 400 mg twice daily and phenytoin in a dose of 300 mg daily for prophylaxis of busulfan-induced seizures in one patient, or brain metastases in two patients. The phenytoin steady state serum concentration was 21.7 mg l−1 and 21.4 mg l−1 in two patients and 5.5 mg l−1 in the third patient (therapeutic range 8–20 mg l−1). The patients were receiving no other co-medication that could have influenced voriconazole metabolism. Evaluation of the voriconazole concentration resulted in switching phenytoin to levetiracetam in one patient, discontinuation of phenytoin because prophylaxis for busulfan-induced seizures was no longer indicated in the second patient, and discontinuation of voriconazole because there was no suspicion any more of an invasive fungal infection in the third patient. CYP genotyping was performed in one patient and did not show any mutation in CYP2C9 or CYP2C19.
These three cases show that, compared with healthy volunteers, the effect of the drug–drug interaction for voriconazole and phenytoin seems to be more profound in ill patients. This can possibly be explained by the large variability in the pharmacokinetics of voriconazole observed in patients [4, 5] which might be caused by several mechanisms including genotypic heterogeneity for CYP2C19 that distinguishes rapid from slow metabolizers. The exposure to voriconazole in patients with already low voriconazole serum concentrations could be further reduced to almost undetectable concentrations by phenytoin as observed in our three patients. A similar case, describing a patient with low voriconazole concentrations during phenytoin treatment, has been reported before and is consistent with our observations [6].
Recently it was shown that CYP2C19*17 polymorphism resulted in significantly lower exposure after a single dose of 200 mg or 400 mg voriconazole [7, 8]. Although voriconazole tends to accumulate considerably with time, the rapid metabolism of voriconazole is expected to result in significantly lower voriconazole exposure. However, the extent of the effect on voriconazole steady state serum concentrations is unknown and needs to be determined at steady state. The prevalence of CYP2C19 polymorphism varies considerably [7, 8] but the difference between our patients and the healthy volunteers cannot be explained solely based on CYP2C19 polymorphisms as in one patient no polymorphism was observed. Besides, in two patients high phenytoin concentrations were observed, which contradicts rapid metabolism.
In our opinion, the combination of voriconazole and phenytoin should be avoided. Levetiracetam, a newer anti-epileptic agent, could be a good alternative for phenytoin in the prophylaxis of busulfan-induced seizures [9] and additionally it could prevent the drug–drug interaction between busulfan and phenytoin [10]. In the case where pre-existing epilepsy is treated with phenytoin, antifungal treatment should preferably be started with a lipid formulation of amphotericin B or anidulafungin as both are not metabolized by CYP450 enzymes. If the combination of phenytoin and voriconazole cannot be avoided, serum concentrations of voriconazole should be monitored at all times and when necessary the dose of voriconazole should be adjusted.
From these cases it can be concluded that a drug–drug interaction between voriconazole and phenytoin in severely ill patients can be more profound and less predictable than in healthy volunteers. Monitoring of voriconazole and phenytoin is needed, but the drug–drug interaction should be avoided whenever possible by using other combinations of anti-epileptic and antifungal drugs.